𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer a cancer and leukemia group B study

✍ Scribed by Stephen L. Graziano; James E. Herndon II; Frederick Richards II; Santo Difino; Caron Modeas; David B. Duggan; Mark R. Green

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
737 KB
Volume
72
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of etoposide and cisplati
Phase II trial of etoposide and cisplatin for refractory small cell lung cancer: A cancer and leukemia group B study
✍ Graziano, Stephen L. ;Lee, Kewchang ;Propert, Kathleen J. ;Tinsley, Roger ;Hayes 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 466 KB 👁 1 views

## Abstract A phase II trial of etoposide and cisplatin for patients with previously treated small cell lung cancer was carried out by CALGB from June 1983 to May 1984. Thirty‐five evaluable patients who had failed one prior chemotherapy regimen were treated with etoposide 80 mg/m^2^ and cisplatin

Phase II trial of ifosfamide and mesna i
Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8552
✍ Case, Delvyn C. ;Anderson, James ;Ervin, Thomas J. ;Gottlieb, Arlan 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 481 KB

Ifosfamide (1.25 g/m2 intravenously/day x 5) with mesna (20% of the ifosfamide dose x six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non-Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29% response rate (9/31) was observed (2 CR and

Phase II trial of ifosfamide/mesna and m
Phase II trial of ifosfamide/mesna and mitoxantrone in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8753
✍ Case, Delvyn C. ;Santarelli, Maria Teresa ;Carey, Robert W. ;Anderson, James ;Go 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 461 KB

## Abstract Ifosfamide (2.0 g/m^2^ intravenously/day × 3) with mesna (400 mg/m^2^ intravenously q 4 h daily × 3) was combined with mitoxantrone (14 mg/m^2^ intravenously × 1) and given on a 3 week schedule to patients with previously treated non‐Hodkgin's lymphoma. In 45 eligible/evaluable patients

A phase I-II study of docetaxel-ifosfami
A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer
✍ Christos Kosmas; Nicolas B. Tsavaris; Thomas Makatsoris; Adimchi Onyenadum; Mari 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 96 KB 👁 1 views

## Abstract In an attempt to develop more effective chemotherapy regimens in advanced nonsmall cell lung cancer (NSCLC), we evaluated docetaxel‐ifosfamide‐cisplatin (DIP) based on our previous experience with paclitaxel‐ifosfamide‐cisplatin. Patients with advanced NSCLC (stages III‐IV), WHO‐PS≤2, n